The ability to localize these nodes with PSMA ligands labelled with gamma-emitting radionuclides such as 99m-technetium (e.g., 99mTc-PSMA-I&S) has moved the needle in terms of radio-guided surgery (RGS) for prostate cancer. This evidence concerns the gene FOLH1 and prostate cancer.